BridgeMD
A trial to learn how well surovatamig (AZD0486) works and how safe it is in adults with certain blood cancers
EU CTIS ID: 2023-505789-27-00
What this study is testing
To evaluate the efficacy of surovatamig (AZD0486) single therapy administered at the Recommended Phase 2 Dose (RP2D) in relapsed or refractory B-cell NHL
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Participant must be 18 years old and above at the time of signing the ICF.
- 2. ECOG performance status of 0 to 2
- 3. Relapsed or refractory disease after at least 2 prior lines of systemic therapy
- 4. Histologically confirmed diagnosis of B-NHL, based on local pathology report, as determined by WHO 2022 classification
- 5. FDG-avid and measurable disease
- 6. Adequate liver, hematological, renal and cardiac function.
You likely can't join if
- 1. Diagnosis of chronic lymphocytic leukemia, Burkitt lymphoma, or Richter’s transformation
- 2. Active CNS involvement by B-NHL.
- 3. Leukemic presentation of disease
- 4. Prior neurotoxicity/ICANS or CRS
- 5. History or presence of clinically relevant CNS pathology (based on investigator assessment)
- 6. Prior allogeneic HSCT or solid organ transplantation within 24 weeks of first planned dose of surovatamig
See the full eligibility criteria
- 1. Participant must be 18 years old and above at the time of signing the ICF.
- 2. ECOG performance status of 0 to 2
- 3. Relapsed or refractory disease after at least 2 prior lines of systemic therapy
- 4. Histologically confirmed diagnosis of B-NHL, based on local pathology report, as determined by WHO 2022 classification
- 5. FDG-avid and measurable disease
- 6. Adequate liver, hematological, renal and cardiac function.
- The above is a summary, other inclusion criteria details may apply
- 1. Diagnosis of chronic lymphocytic leukemia, Burkitt lymphoma, or Richter’s transformation
- 2. Active CNS involvement by B-NHL.
- 3. Leukemic presentation of disease
- 4. Prior neurotoxicity/ICANS or CRS
- 5. History or presence of clinically relevant CNS pathology (based on investigator assessment)
- 6. Prior allogeneic HSCT or solid organ transplantation within 24 weeks of first planned dose of surovatamig
- The above is a summary, other exclusion criteria details may apply
The study team makes the final eligibility decision.
Where it's taking place
- China
- Brazil
- Korea, Republic of
- United Kingdom
- Japan
- Hong Kong
- United States
- Taiwan
- Australia
- Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include China; Brazil; Korea, Republic of; United Kingdom; Japan; Hong Kong and 4 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.